Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 12, 2025 | June 16, 2025 |
| Clearside Biomedical, Inc.CLSD · Entity 82875 | Director | June 20, 2024 | June 21, 2024 |
| Endo International plcENDP · Entity 124463 | Director | June 11, 2021 | June 15, 2021 |
| PhaseBio Pharmaceuticals IncPHAS · Entity 113305 | Director | May 19, 2023 | May 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 99,138 |
Reported balance
After 2025-06-12 transaction · row 1
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 12,500 · Balance 99,138 F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2035-06-12 | Direct | 27,181 |
Reported balance
After 2025-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-12 · Grant · Acquired 27,181 · Balance 27,181 F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
Clearside Biomedical, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2034-06-19 | Direct | 45,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 45,000 · Balance 45,000 F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date.
Endo International plc
Report date June 11, 2021 · Filed June 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 116,140 |
Ending reported balance
After 2021-06-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-06-11 · Grant · Acquired 47,924 · Balance 139,143 F1: These ordinary shares were granted to Dr. Hutson on June 11, 2021 in consideration of her services on Endo International plc's Board of Directors. Row 2 · 2021-06-11 · Tax withholding · Disposed 23,003 · Balance 116,140 F2: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Hutson's tax withholding obligations on shares acquired on June 11, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: These ordinary shares were granted to Dr. Hutson on June 11, 2021 in consideration of her services on Endo International plc's Board of Directors.
F2: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Hutson's tax withholding obligations on shares acquired on June 11, 2021.
PhaseBio Pharmaceuticals Inc
Report date May 19, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,510 |
Reported balance
After 2023-05-19 transaction · row 1
1 source rowRow 1 · 2023-05-19 · Exercise / conversion · Acquired 3,750 · Balance 37,510 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-19 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. |
| Common StockSEC Table I · non-derivative | IndirectHeld in an individual retirement account for the benefit of the Reporting Person | 4,000 |
Reported balance
Holding disclosure · report date 2023-05-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2021 Filed Jun 4, 2021 18:05 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001169245-21-000060 · wf-form4_162284430349995.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the 2022 annual meeting, subject to the reporting person's continuous service through each such date Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 317 | $15.77 | $4,999.09 |
DisclosureSEC source: 0001127602-21-018492 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,073 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0001127602-21-018179 · form4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 16:50 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | PurchaseCommon Stock | 5,000 | $3.11 | $15,525.00 |
DisclosureSEC source: 0001209191-21-020488 · doc4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:53 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 463 | $10.78 | $4,991.14 |
DisclosureSEC source: 0001127602-21-008761 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,756 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 978 | $5.11 | $4,997.58 |
DisclosureSEC source: 0001127602-20-030287 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,293 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 20:44 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,204 | $4.15 | $4,996.60 |
DisclosureSEC source: 0001127602-20-024646 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,315 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 16:35 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037942 · doc4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 18, 2021. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 16:06 UTC | Endo International plc ENDP · Entity 124463 | Tax withholdingOrdinary Shares | 12,245 | $3.43 | $42,000.35 |
DisclosureSEC source: 0001593034-20-000050 · wf-form4_159233797361893.xml · nonDerivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,219 F2 · kind: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Hutson's tax withholding obligations on shares acquired on June 12, 2020. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 16:06 UTC | Endo International plc ENDP · Entity 124463 | GrantOrdinary Shares | 25,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001593034-20-000050 · wf-form4_159233797361893.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,464 F1 · kind: These ordinary shares were granted to Dr. Hutson on June 12, 2020 in consideration of her services on Endo International plc's Board of Directors. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 18:57 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001169245-20-000063 · wf-form4_159139782229645.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the 2021 annual meeting, subject to the reporting person's continuous service through each such date Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:20 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 2,224 | $4.50 | $9,996.88 |
DisclosureSEC source: 0001127602-20-018711 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,111 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000 Read SEC document |
| May 20, 2020 Filed May 21, 2020 16:50 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | PurchaseCommon Stock | 5,000 | $1.85 | $9,250.00 |
DisclosureSEC source: 0001209191-20-031325 · doc4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001127602-20-016569 · form4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-05-12 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 16:58 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-20-025448 · doc4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-04-20 F1 · derivative.exercise_date: This option will vest and become exercisable in 36 equal monthly installments, subject to the Reporting Person's continuous service as of such vesting dates. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 21:50 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 3,333 | $3.00 | $9,999.00 |
DisclosureSEC source: 0001127602-20-009065 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,887 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000 Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:12 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 3,508 | $2.85 | $9,997.80 |
DisclosureSEC source: 0001127602-19-034165 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,554 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:10 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 10,000 | $1.45 | $14,500.00 |
DisclosureSEC source: 0001127602-19-033022 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,046 Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 20:12 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 3,344 | $2.99 | $9,998.56 |
DisclosureSEC source: 0001127602-19-027862 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,046 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 19:30 UTC | Endo International plc ENDP · Entity 124463 | Tax withholdingOrdinary Shares | 25,829 | $4.46 | $115,197.34 |
DisclosureSEC source: 0001209191-19-037300 · doc4.xml · nonDerivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,953 F2 · kind: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Hutson's tax withholding obligations on shares acquired on June 12, 2019. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 19:30 UTC | Endo International plc ENDP · Entity 124463 | GrantOrdinary Shares | 53,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037300 · doc4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,782 F1 · kind: These ordinary shares were granted to Dr. Hutson on June 12, 2019 in consideration of her services on Endo International plc's Board of Directors. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001127602-19-020310 · form4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-29 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| May 09, 2019 Filed May 13, 2019 16:36 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $13.23 | $0.00 |
DisclosureSEC source: 0001209191-19-029352 · doc4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-05-09 F1 · derivative.exercise_date: The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the date of the 2020 annual meeting, subject to the reporting person's continuous service through each such date Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:47 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantEmployee Stock Option (right to buy) · Derivative | 8,900 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-19-015032 · doc4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,900 Underlying: Common Stock · 8,900 shares Expires 2029-02-27 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal monthly installments over 36 months from October 17, 2018, subject to the reporting person's continued service through each such date. Read SEC document |
| December 17, 2018 Filed Dec 17, 2018 16:19 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | PurchaseCommon Stock | 1,000 | $4.46 | $4,460.00 |
DisclosureSEC source: 0001209191-18-062934 · doc4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held in an individual retirement account for the benefit of the reporting person Disclosed balance after: 1,000 Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 16:03 UTC | Endo International plc ENDP · Entity 124463 | SaleOrdinary Shares | 10,000 | $12.83 | $128,300.00 |
DisclosureSEC source: 0001209191-18-058924 · doc4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,970 F1 · shares: These sales of ordinary shares were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 13:35 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001127602-18-021730 · form4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-20 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning July 20, 2018. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 16:09 UTC | Endo International plc ENDP · Entity 124463 | Tax withholdingOrdinary Shares | 15,019 | $7.67 | $115,195.73 |
DisclosureSEC source: 0001209191-18-037210 · doc4.xml · nonDerivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,970 F2 · kind: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Hutson's tax withholding obligations on shares acquired on June 8, 2018. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 16:09 UTC | Endo International plc ENDP · Entity 124463 | GrantOrdinary Shares | 31,291 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-037210 · doc4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,989 F1 · kind: These ordinary shares were granted to Dr. Hutson on June 8, 2018 in consideration of her services on Endo International plc's Board of Directors. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 18:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,555 | $6.43 | $9,998.65 |
DisclosureSEC source: 0001127602-18-019686 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,702 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 19:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 2,012 | $4.97 | $9,999.64 |
DisclosureSEC source: 0001127602-18-009560 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,147 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 20:50 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,968 | $5.08 | $9,997.44 |
DisclosureSEC source: 0001127602-17-033780 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,135 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 15:27 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,960 | $5.10 | $9,996.00 |
DisclosureSEC source: 0001127602-17-026878 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,167 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 21:38 UTC | Endo International plc ENDP · Entity 124463 | Tax withholdingOrdinary Shares | 11,488 | $11.49 | $131,997.12 |
DisclosureSEC source: 0001209191-17-039328 · doc4.xml · nonDerivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,698 F3 · kind: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Hutson's tax withholding obligations on shares acquired. F2 · balance_after: This number represents ordinary shares, of which 6,515 have been deferred under Endo International plc's directors deferred compensation plan. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 21:38 UTC | Endo International plc ENDP · Entity 124463 | GrantOrdinary Shares | 23,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039328 · doc4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,186 F1 · kind: These ordinary shares were granted to Dr. Hutson on June 9, 2017 in consideration of her services on Endo International plc's Board of Directors. F2 · balance_after: This number represents ordinary shares, of which 6,515 have been deferred under Endo International plc's directors deferred compensation plan. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:01 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,941 | $5.15 | $9,996.15 |
DisclosureSEC source: 0001127602-17-020296 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,207 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| May 24, 2017 Filed May 25, 2017 15:45 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001127602-17-019331 · form4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning June 24, 2017. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 10:24 UTC | Endo International plc ENDP · Entity 124463 | SaleOrdinary Shares | 5,325 | $10.82 | $57,616.50 |
DisclosureSEC source: 0001209191-17-019749 · doc4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,252 F1 · shares: These sales of ordinary shares were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: This number represents ordinary shares, of which 6,515 have been deferred under Endo International plc's directors deferred compensation plan. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 20:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,602 | $6.24 | $9,996.48 |
DisclosureSEC source: 0001127602-17-009568 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,266 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 19:06 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,788 | $5.59 | $9,994.92 |
DisclosureSEC source: 0001127602-16-068908 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,664 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 19:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 2,433 | $4.11 | $9,999.63 |
DisclosureSEC source: 0001127602-16-061903 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,876 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.